FBLG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.087

-2.78%

-0.090

-35.71%

-0.090

-25%

Estimates Revision

The market is revising No Change the revenue expectations for FibroBiologics, Inc. (FBLG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -22.88%.

EPS Estimates for FY2025

Revise Upward

+0.54%

In Past 3 Month

Stock Price

Go Down

-22.88%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast FBLG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBLG is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

4.50

High

5.00

Current: 0.000

Low

4.00

Averages

4.50

High

5.00

H.C. Wainwright

Buy

downgrade

$10 -> $5

2025-11-05

Reason

H.C. Wainwright

Price Target

$10 -> $5

2025-11-05

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on FibroBiologics to $5 from $10 and keeps a Buy rating on the shares. The firm adjusted the company's model to reflect an updated share count and tempered factor of patients receiving FibroBiologics' novel diabetic foot ulcer treatment pending further clinical validation.

H.C. Wainwright

Matthew Caufield

Buy

downgrade

$12 -> $10

2025-08-05

Reason

H.C. Wainwright

Matthew Caufield

Price Target

$12 -> $10

2025-08-05

downgrade

Buy

Reason

H.C. Wainwright analyst Matthew Caufield lowered the firm's price target on FibroBiologics to $10 from $12 and keeps a Buy rating on the shares. The firm says the company's progress continues across therapeutic fibroblast development.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$16

2025-04-09

Reason

D. Boral Capital

Jason Kolbert

Price Target

$16

2025-04-09

Maintains

Strong Buy

Reason

FibroBiologics announced a significant advancement in neurodegenerative disease research. Leveraging the Cuprizone animal model, FibroBiologics has demonstrated that intravenous fibroblasts can facilitate remyelination. FibroBiologics' Cuprizone animal model study demonstrated a statistically significant increase in myelin expression within seven weeks after both single and multiple dose fibroblast treatments. This confirms FibroBiologics' previous report of remyelination with the Experimental Autoimmune Encephalomyelitis animal model. "This confirmation by our talented team of researchers demonstrates that fibroblasts can support the regeneration of myelin sheath, marking a potentially significant step in the utilization of a cell-based therapeutic in regenerative medicine," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$16

2025-04-01

Reason

D. Boral Capital

Jason Kolbert

Price Target

$16

2025-04-01

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$12

2025-04-01

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$12

2025-04-01

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$16

2025-03-04

Reason

D. Boral Capital

Jason Kolbert

Price Target

$16

2025-03-04

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Fibrobiologics Inc (FBLG.O) is -0.67, compared to its 5-year average forward P/E of -8.66. For a more detailed relative valuation and DCF analysis to assess Fibrobiologics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.66

Current PE

-0.67

Overvalued PE

1.16

Undervalued PE

-18.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

FBLG News & Events

Events Timeline

No data

News

9.0

2025-12-31Globenewswire

FibroBiologics Files IND for CYPS317 Clinical Trials Targeting Psoriasis

9.0

2025-12-31Newsfilter

FibroBiologics Files IND for CYPS317 Clinical Trials Targeting Psoriasis

8.5

2025-12-16Globenewswire

FibroBiologics Closes $1.7 Million Registered Direct Offering

People Also Watch

Frequently Asked Questions

What is Fibrobiologics Inc (FBLG) stock price today?

The current price of FBLG is 0.338 USD — it has increased 2.42 % in the last trading day.

What is Fibrobiologics Inc (FBLG)'s business?

FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

What is the price predicton of FBLG Stock?

What is Fibrobiologics Inc (FBLG)'s revenue for the last quarter?

Fibrobiologics Inc revenue for the last quarter amounts to -5.04M USD, increased 50.30 % YoY.

What is Fibrobiologics Inc (FBLG)'s earnings per share (EPS) for the last quarter?

Fibrobiologics Inc. EPS for the last quarter amounts to -3978000.00 USD, increased 52.01 % YoY.

What changes have occurred in the market's expectations for Fibrobiologics Inc (FBLG)'s fundamentals?

How many employees does Fibrobiologics Inc (FBLG). have?

Fibrobiologics Inc (FBLG) has 13 emplpoyees as of January 11 2026.

What is Fibrobiologics Inc (FBLG) market cap?

Today FBLG has the market capitalization of 22.48M USD.